fingolimod hydrochloride has been researched along with Leishmaniasis, Cutaneous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carreón Guarnizo, E; García Vazquez, E; Hernández Clares, R; Meca Lallana, JE; Sánchez Pedreño, P | 1 |
| Bueno, V; Cury, PM; de Paula, DM; Lopes, CT; Valero-Lapchik, VB | 1 |
2 other study(ies) available for fingolimod hydrochloride and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leishmaniasis, Cutaneous; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Leishmania (Leishmania) amazonensis infection in mice treated with FTY720.
Topics: Animals; CD4-Positive T-Lymphocytes; Fingolimod Hydrochloride; Flow Cytometry; Hindlimb; Immunosuppressive Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Lymphocyte Count; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Spleen | 2010 |